Integrating Electromyography and Sonographic Imaging for Evidence-Based Physical Therapy for Chronic Pelvic Pain
Principal Investigator: Shawn C. Roll PhD, OTR/L, RMSKS, FAOTA, FAIUM
Co-Investigator: Jason Kutch
Period
Jul 2012 – Jun 2013
Total funding
$30,000
Our team used sonography to evaluate the physical mechanisms underlying Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). We developed and validated a scanning protocol to evaluate the muscles of the male pelvic floor using a transperineal approach. This protocol can be used to evaluate difference among individuals with and without CP/CPPS, as well as identify variations within patients with CP/CPPS. The approach may also be useful for targeting treatments to areas of hyper-contraction (e.g., trigger points) or as a biofeedback tool to train patients in both relaxation techniques and proper exercises for these muscles.
Abstract
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is present in 6-12% of men and is the most frequent urological diagnosis for men younger than 50 years old. CP/CPPS significantly reduces quality of life, even below that of other prevalent chronic conditions (e.g. congestive heart failure, diabetes). CP/CPPS patients are a highly heterogeneous group, with varied pathophysiology. One identified mechanism for CP/CPPS is involuntary localized neuromuscular activity. Physical therapy has emerged as one primary treatment modality for CP/CPPS, but up to 41% of patients report little to no improvement or a worsening of symptoms after a course of physical therapy treatment. There is currently no method for stratifying CP/CPPS patients to ensure that appropriate treatments are being provided. There is an urgent need to identify patients, before treatment begins, who are likely to respond positively to physical therapy. We aim to identify a set of neuromuscular biomarkers for CP/CPPS patients using sonographic imaging (i.e. 2D & 3D, spectral analysis, and elastography) and EMG recording, and to determine the ability of neuromusuclar biomarkers to enhance current clinical phenotyping.
Funding
Type | Source | Amount |
---|---|---|
Intramural | USC Keck School of Medicine / Southern California Clinical Translational Science Institute (SC CTSI) | $30,000 |